The "brain-gut" peptide ghrelin, which mediates food-seeking behaviors, is recognized as a very strong endogenous modulator of dopamine (DA) signaling. Ghrelin binds the G protein-coupled receptor GHSR1a, and administration of ghrelin increases the rewarding properties of psychostimulants while ghrelin receptor antagonists decrease them. In addition, the GHSR1a signals through barrestin-2 to regulate actin/stress fiber rearrangement, suggesting barrestin-2 participation in the regulation of actin-mediated synaptic plasticity for addictive substances like cocaine. The effects of ghrelin receptor ligands on reward strongly suggest that modulation of ghrelin signaling could provide an effective strategy to ameliorate undesirable behaviors arising from addiction. To investigate this possibility, we tested the effects of ghrelin receptor antagonism in a cocaine behavioral sensitization paradigm using DA neuron-specific barrestin-2 KO mice. Our results show that these mice sensitize to cocaine as well as wild-type littermates. The barrestin-2 KO mice, however, no longer respond to the locomotor attenuating effects of the GHSR1a antagonist YIL781. The data presented here suggest that the separate stages of addictive behavior differ in their requirements for barrestin-2 and show that pharmacological inhibition of barrestin-2 function through GHSR1a antagonism is not equivalent to the loss of barrestin-2 function achieved by genetic ablation. These data support targeting GHSR1a signaling in addiction therapy but indicate that using signaling biased compounds that modulate barrestin-2 activity differentially from G protein activity may be required.
The ghrelin receptor GHSR1a is G protein-coupled receptor (GPCR) that regulates diverse physiological processes such as growth hormone secretion, food intake, mood and memory formation (for review see (Muller et al., 2015) . It is expressed directly on DA neurons in the VTA and has a pivotal role in mediating dopamine-dependent reward (Abizaid et al., 2006; Zigman, Jones, Lee, Saper, & Elmquist, 2006) . GHSR1a activation in the VTA increases DA release in the nucleus accumbens (NAc) and stimulates locomotor activity in response to the natural ligand ghrelin (Abizaid et al., 2006; Jerlhag et al., 2007; Quarta et al., 2009) . Most significantly, the pharmacological antagonism of the GHSR1a reverses cocaine, amphetamine, morphine and alcohol-induced hyperactivity and the rewarding properties of these drugs in tests of conditioned place preference and alcohol intake (Engel, Nylander, & Jerlhag, 2015; Jerlhag, Egecioglu, Dickson, & Engel, 2010; Jerlhag et al., 2009 ).
The GHSR1a signals through both heterotrimeric G proteins and separately through a barrestin pathway (Evron et al., 2014) , barrestin-1 and -2 are also known as arrestins 2 and 3. Using a model cell system, we identified measurable GHSR1a /barrestin signaling selectivity in which GHSR1a barrestin recruitment led to RhoA activated, actin/stress fiber rearrangement (Evron et al., 2014) . Potentially important to behavior and reward, actin regulation is associated with the cocaine-induced expansion of NAc dendritic spines (Dietz et al., 2012) . Finding biased ligands that selectively engage either G-protein or barrestin signaling is an ever-growing strategy for dissecting the signaling of GPCRs regulating reward-associated behaviors. Examples of biased ligands have already been identified for neurotensin and dopamine receptors (Allen et al., 2011; Peddibhotla et al., 2013) .
Alternatively, genetic strategies remain useful to study signaling bias in the context of the rewarding properties of drugs of abuse. Employing a genetic approach with a global barrestin-2 KO mouse model, our laboratory has shown that barrestin-2 regulates psychostimulant-induced DAdependent behaviors (Beaulieu et al., 2005; Bohn et al., 2003; Urs, Daigle, & Caron, 2011) .
The phenomenon that repeated exposure to drugs of abuse results in a progressive and long-lasting enhancement of the locomotor response is termed psychomotor (or locomotor) sensitization. Locomotor sensitization is a commonly used assay in the modeling of psychostimulant abuse in animals. Although locomotor sensitization is not a direct correlate of reward, this response is thought to be due to alterations in neuronal plasticity that occur over the course of multiple exposures to psychostimulants. Furthermore, locomotor sensitization has been proposed to correspond to certain aspects of drug addiction such as compulsive drug-seeking behavior (Robinson & Berridge, 1993; Vanderschuren & Kalivas, 2000; Vezina & Leyton, 2009) .
We now report a role for barrestin-2 in early phases of drug addiction. We observed in a cocaine-sensitized mouse model that genetically ablating barrestin-2 in pre-synaptic DA neurons prevents the GHSR1a antagonist YIL781 from inhibiting cocaine-induced hyperlocomotion. In contrast, deleting barrestin-2 does not affect the preceding phase of cocaine sensitization. This suggests that barrestin-2 function differentially regulates distinct stages of drug addiction. Thus, our findings have important pharmacological implications for matching stage with therapy.
| M A TE RI A L S A ND M E TH ODS

| Animals and drugs
Adult age-matched male and female (8-12 week old and 25-35 g body weight) C57BL/6 J (The Jackson Laboratory Bar Harbor, ME), global barrestin-2 KO and two distinct lines of dopamine neuron-specific barrestin-2 KO mice (defined as DAbarr2KO-1 and DAbarr2KO-2) and WT littermate mice were used. To obtain DAbarr2KO mice, a barrestin-2 flox/flox mouse line was crossed to two-independent dopamine transporter Cre mouse lines, respectively (for DAbarr2KO-1: DAT-Cre, SG62 GENSAT, for DAbarr2KO-2: DAT-Cre #006660 The Jackson Laboratory). All mouse lines used in the experiments had or were backcrossed to the same C57BL/6 J genetic background. All mice were group housed and maintained at a 12/12 hr light/dark cycle. Experiments were carried out at the beginning of the light cycle. Tap water and standard laboratory chow were supplied ad libitum, except for the time of testing. Mice were randomly assigned into treatment groups and the individuals performing injections were blind to the genotype of the injected animal. GHSR1a antagonist YIL781 (5, 10 or 20 mg/kg, Tocris 3959) and cocaine HCl (5 or 20 mg/kg, Sigma C5776) were dissolved in saline and were injected intraperitoneally (i.p.) according to the experimental schedule. Saline was used as vehicle controls. All drugs were injected at a volume of 10 ml/kg body weight. All mouse studies were conducted in accordance with the National Institutes of Health Guidelines for Animal Care and Use and with an approved animal protocol from the Duke University Animal Care and Use Committee.
| Cultured cell-based assays 2.2.1 | Ca21 mobilization
The calcium response of GHSR1a receptor was measured using HEK293 cells that permanently expressed both the human GHSR1a and mitochondrial apoaequorin (Evron et al., 2014; Rizzuto, Simpson, Brini, & Pozzan, 1992) . On Day 0 the cells were plated at 7 3 10 6 cell on a 10 cm diameter culture plate. The following day (test day) growth media was replaced with cMEM 1 HEPES 1 GlutaMAX (OptiMEM, Gibco, 51985034) for 2-4 hr before adding 2.5 ml/ml coelenterazine-h (1 mM stock solution, (Promega, 2011) 
| bArrestin-2 recruitment
The activation of barrestin2 by the GHSR1a was assessed using a U2OS cell line permanently expressing the GHSR1a-(vasopressin receptor2-tail) chimera (GHSR1a-V2T) and green fluorescent protein (GFP) tagged barrestin2. On Day 1, stable cells were split into MGB101-1-2-LG glass-bottom 384-well plates (MatriCal, Spokane, WA). Each well contained 30 ll aliquots of 8,000 cells in Minimum Eagle's medium (MEM) containing 10% fetal bovine serum (FBS) and 100 U/ml penicillin/streptomycin (Life Technologies, Grand Island, NY). The plates were incubated overnight at 378C in 5% CO2, and on the following day the media was changed to 30 ll clear MEM without serum. Increasing doses of YIL781 in 5% DMSO were added to the wells and diluted 10-fold to reach final concentration. To test the antagonist property of YIL781, 1 mM of the GHSR1a agonist L585 was injected into each well, the plates were returned to the incubator for 40 min, and then the cells were fixed by adding 30 ll of 2% paraformaldehyde-phosphate buffered saline (PBS) to each well. Plates were stored at 48C until analysis at 488 nm on a robotic imager (ImageXpress Ultra, Molecular Devices, Sunnyvale, CA). Images were analyzed using a wavelet algorithm to measure formation of fluorescence aggregates (Evron et al., 2014) . Image results were also visually confirmed
| Cre expression verification
DAT-Cre mice (SG62 GENSAT and Jackson Laboratory #006660) were bred to floxed barrestin-2 mice (Urs et al., 2015) for homozygosity at the floxed allele and were used for behavioral experiments. To check for Cre activity in dopamine neurons, the SG62 GENSAT DAT-Cre line was also bred to a Cre reporter mouse line consisting of a Cre-dependent GFP-tagged ribosomal L10a subunit. For the DAT-Cre line from Jackson Laboratory, Adeno-associated virus serotype 10 containing a Cre-inducible hM3D-mCherry was stereotactically injected bilaterally into the VTA/SNc (AP:
23.1 mm ML: 60.6 mm DV: 24.5 mm). Cre activity for both DAT-Cre mouse lines was verified histologically. Briefly, the mice were transcardially perfused with 2% formaldehyde with heparin in PBS. Brains were removed and post-fixed overnight. On the next day, 200 lm thick sections were cut with a vibratome (VT1000S, Leica) and were blocked in Fish Gelatin Extract in PBS and then incubated with primary rabbit antibodies against tyrosine hydroxylase (Invitrogen, OPA-04050, 1:1,000) overnight at 48C. After incubation with primary antibody, the sections were washed in PBS and incubated for 1 hr at RT with Goat anti-rabbit alexa fluor 488 or 568 (1:1,000). Sections were then washed and mounted on slides with vectashield and coverslipped. Images were taken on an Axiozoom fluorescent dissecting scope with the appropriate filter cubes (Zeiss).
| Locomotor activity
Locomotor activity was measured with an Omnitech Digiscan activity monitor (20 3 20 cm; Accuscan Instruments, Columbus, OH) at 5 min intervals, and data were analyzed for the total distance traveled per interval over 120 min (Bohn et al., 2003) . The total distance traveled over a 30 min period post-cocaine injection was also calculated to analyze the outcome of pre-treatments on the peak effect of cocaine. Mice were allowed to acclimatize to the activity monitor for 30 min before any drug treatments. Drugs were administered at various time points depending on the experiment as shown on the figures.
| Blood pressure measurement
To assess the possible effect of YIL781 on blood pressure, hemodynamic measurements were performed on WT mice anesthetized with a mixture of Ketamine (100 mg/kg) and Xylazine (10 mg/kg). A 1.4-Fr pressure-conductance catheter (Millar Instruments, Houston, TX) was inserted retroaortically into the LV to record hemodynamics. Subsequently, parallel conductance (Vp) was determined by 10 ml injection of 15% saline into the right jugular vein to establish the parallel conductance of the blood pool. The derived Vp was used to correct the P-V loop data. Data were recorded digitally at 1,000 Hz and analyzed with pressure volume analysis software (PVAN data analysis software version 3.3; Millar Instruments). Each mouse received the following injection scheme, vehicle i.p. followed after 10 min with either 5, 10 or 20 mg/kg i.p. YIL781.
| Locomotor sensitization to cocaine
Mice were sensitized as described (Bohn et al., 2003) . 
| Statistical analyses
For dose-response curves data were analyzed by nonlinear regression to obtain ECmax, EC50 and IC50 values. Locomotor data were analyzed by a standard one-or two-way ANOVA test for comparison between genotypes, treatments or doses (GraphPad Prism 7.02 software). Individual genotypes, treatments or doses were compared using Tukey's post hoc test whenever ANOVA showed significance to either treatment or a treatment 3 time interaction. For the cocaine sensitization data, areas under the curve was also calculated in 15 min consecutive segments. A probability value of p < .05 was considered as statistically significant. Statistical results are described in the figure legends. All data are presented as mean 6 SEM.
| R E SU LTS
YIL781 is reported to competitively block ghrelin peptide binding to GHSR1a as well as G protein binding and barrestin-2 activation (Esler et al., 2007; Evron et al., 2014) . We verified these properties suggesting that YIL781 is a full GHSR1a antagonist using a combination of in cellulo assays for Gq-mediated Ca21 response (Figure 1a ,b) and barrestin-2 translocation (Figure 1c,d ). The data show that YIL781 has no agonist activity of its own (Figure 1a ,c) and dose dependently and with low nanomolar affinity blocks GHSR1a calcium ( Figure 1b ) and barrestin-2 (Figure 1d ) responses of the potent small molecule GHSR1a agonist L-692,585. Since YIL781 does not activate the receptor when applied alone, it is also not a weak partial agonist. These results suggest that YIL781 should be able to antagonize GHSR1a-based regulation of locomotion occurring through both the receptor's G-protein and barrestin-2 signaling pathways.
We began in vivo locomotor testing in WT C57BL/J6 mice exposed to graded i.p. doses of 5, 10 and 20 mg/kg YIL781 followed 15 min later by an i.p. dose of either vehicle or cocaine, Figure 2a . Each tested concentration of YIL781 significantly reduced cocaine-induced hyperlocomotion.
However, post-cocaine, the total distance traveled over 30 min was significantly reduced only in the 10 and 20 mg/kg YIL781 treated mice, Rodent open field activity can be affected by either high or low blood pressure. High blood pressure delays the habituation to the arena (Sestakova, Puzserova, Kluknavsky, & Bernatova, 2013) while low blood pressure may impair motor performance and environment exploration. It has been reported that peripheral injection of ghrelin and other GHSR1a agonists decrease blood pressure, and this occurs with or without a decrease in sympathetic nerve discharge (Callaghan et al., 2012 ). Therefore, we tested the effect of i.p. YIL781 on blood pressure and heart rate under conditions similar to those used in the locomotor sensitization experiments. We found no significant difference between vehicle and i.p. administered YIL781 at 5, 10 and 20 mg/kg (Figure 4) , suggesting that YIL781's locomotor effect is not due to blood pressure fluctuations.
To examine in presynaptic DA neurons whether the inhibitory effect of YIL781 on locomotor sensitization to cocaine is mediated by barrestin-2, we generated KO mice by crossing dopamine transporter (DAT)-Cre positive mice with barrestin2-flox/flox mice. This deletes barrestin-2 selectively from the DAT expressing DA positive neurons. In comparison to global barrestin-2 KOs, these limited KO mice (DAbarr2KO) better isolate the CNS circuits involved in rewarding behaviors. 
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It has been reported that even among littermates, mouse strains expressing Cre may have quite variable expression patterns (Heffner et al., 2012) . Consequently, they may have also unexpected and variable phenotypes (Heffner et al., 2012; Vuong, Perez de Sevilla Muller, Hardi, McMahon, & Brecha, 2015) . Our first attempt at DAbarr2KO mice using SG62 GENSAT DAT-Cre resulted in apparently limited Cre expression. Most likely, speed congenic breeding to a C57BL/J6 background produced a DAT-Cre mosaic in DA1 neurons (Figure 5a ). We therefore generated a new line of DA neuron selective barrestin-2 KO by crossing barrestin2-flox/flox mice with an independent line of C57BL/6 J background DAT-Cre mice (Figure 5b ; DAT-Cre #006660) to control for variable Cre expression. The new KO mice had much more extensive Cre expression, implying relatively greater barrestin-2 depletion in the target neurons. In fact, the second DAT-Cre mouse line we used has been shown to have the highest fidelity for Cre expression in DA neurons, addressing what has been a problem in the field (Lammel et al., 2015) . Importantly, together the two KO lines offered an opportunity to determine upper limits on the distribution of ghrelin receptor containing cells involved in dopamine regulation.
As shown in Figure 5 , both DAbarr2KO-1 and DAbarr2KO-2 mice showed more sensitivity to cocaine on the first day of injections (Day 1, Figure (Figure 5g-j) , a 10 mg/kg YIL781 pre-treatment reduced 5 mg/kg cocaine-induced locomotion in the WT mice but not in either of the DAbarr2KO-1 and DAbarr2KO-2 lines. These data suggest that intact barrestin-2 signaling in DA neurons is not necessary for cocaine sensitization but surprisingly barrestin-2 is required for the inhibitory effect of YIL781 on cocaine-mediated hyperlocomotion. Furthermore, our data suggest that a subset of cells may be sufficient to cause the behavioral phenotype since we did not observe a significant difference between the two KO mouse lines in their response to YIL781.
We employed two alternative approaches to confirm that barrestin-2 depletion underlies the observations described in Figure 5 above. The first approach attempted to use barrestin-2 specific antibodies to directly assess the extent of Cre-dependent barrestin-2 knockdown in brain slices.
However, the antibodies available to us for in situ immunochemical staining were unable to discriminate local changes in barrestin-2 expression vs.
barrestin-1 and background. We therefore employed a second approach to assess the effects of barrestin-2 depletion that utilized a validated whole-body barrestin-2 knockout mouse (Bohn et al., 1999) . These KO mice and their littermate controls were sensitized (Figure 6a ,b) and treated with YIL781 (Figure 6c,d) as above. The whole-body KO mice behaved like the DAbarr2KO-1 and DAbarr2KO-2 animals. YIL781 effectively reduced expression of cocaine sensitization in the wild-type littermate controls, but in contrast no such effect was evident in the whole-body barrestin-2 KO animals (Figure 6c,d ). These data confirm that barrestin-2 is required for YIL781 to attenuate expression of cocaine sensitization.
| D I SCUSSION
Over the past three decades our laboratory has investigated addiction in the context of DA signaling. Drug addiction can be viewed as a composite neurological disorder composed of a pre-addictive phase followed by three alternating stages: (1) preoccupation/anticipation (craving), (2) binge/ intoxication and (3) withdrawal/negative affect (Koob & Volkow, 2010; Volkow, Koob, & McLellan, 2016 ). An ideal addiction therapy would seek to reestablish normal brain function by disrupting this ongoing cycle at one or more of its stages, with the ultimate goal of preventing relapse. To date, there are limited pharmacological tools to achieve these overall goals let alone specifically target and interdict any one particular stage. Important factors governing this limitation are the functional heterogeneity of participating receptors, the large spectrum of available signaling pathways, and the complex circuitry that participates in regulating the formation and loss of addictive behaviors. A minimally invasive approach to blocking the addictive cycle is desirable and potentially pharmacologically obtainable. Here, we showed that both WT mice and DA-neuron specific barrestin-2 KO mice can be sensitized to cocaine. In contrast, the GHSR1a antagonist YIL781 cannot attenuate cocaine-induced locomotion in the KO mice.
This indicates that barrestin-2 activity at GHSR1a plays a distinct role in regulating an established cocaine-induced behavior. Thus, this drug seeking stage should be amenable to pharmacological therapy aimed at GHSR1a/barrestin-2 activity whereas the pre-addictive drug sensitization phase would not. This provides the first evidence for a selective requirement of barrestin-2 activity in the distinct stages of addictive behavior.
Our observation that barrestin-2 KO mice displayed reduced sensitivity to cocaine on Day 1 but WT-like expression of cocaine sensitization on Day 10 (test day), extend the findings of Bohn et al. (2003) . Bohn et al. reported a small, non-significant reduction in cocaine responsivity in barrestin-2 KOs prior to sensitization and both genotypes are shown to sensitize to the same extent. Our ability to identify a significant genotype effect in unsensitized mice here may stem from the larger cohort (n 5 24 vs.12 mice/genotype). The cocaine sensitization results with DA neuronselective KO of barrestin-2 are also in agreement with those reported with global barrestin-2 KO, where the mice in the latter case have basal and cocaine-induced extracellular DA levels similar to their WT littermates (Bohn et al., 2003) . A possible mechanism to explain our sensitization observations lies in the partial redundancy exhibited by the two barrestin isoforms in cell models. Alternatively, because locomotor sensitization may predominantly involve enhanced postsynaptic DA receptor sensitivity on NAc medium spiny neurons (Koob & Nestler, 1997) , knocking out barrestin-2 pre-synaptically in VTA DA neurons may only have a minor effect on behavioral sensitization.
Changes in extracellular DA in the striatum regulate locomotion, and a functionally significant fraction of DA release is controlled by GHSR1a signaling (Jerlhag et al., 2007; Quarta et al., 2009) . We believe that antagonists like YIL781 may reduce DA release by inhibiting excitatory glutamatergic neurotransmission because an injection of ghrelin increases it (Abizaid et al., 2006 ; Figure 7b ). Characterizing the role of barrestin-2 in YIL781/GHSR1a modulation of hyperlocomotion in cocaine-sensitized mice requires that we reconcile two seemingly contradictory results. First, pharmacological blockade of the ghrelin receptor in sensitized WT mice prevents both G protein and barrestin-2 activity and reverses cocaineinduced hyperlocomotion. Thus, reducing barrestin-2 activity by genetic ablation should also reduce hyperlocomotion. However, cocaine-sensitized mice lacking barrestin-2 globally or selectively in presynaptic DA neurons do not respond to YIL781, and hyperlocomotion persists with cocaine exposure. This is exactly opposite to what is expected and appears to rule out both G protein and barrestin regulation of hyperlocomotion at the GHSR1a. To explain these observations, we need to address how genetic depletion of barrestin-2 activity in the KO differs from its pharmacological loss/inhibition of the receptor. To explain the role of barrestin-2 in YIL781/GHSR1a modulation of hyperlocomotion in cocaine-sensitized mice, we first invoke a basic axiom of signaling theory; most all biological processes can be modeled by logistic (sigmoid) curves (Black & Leff, 1983) . Sigmoid functions are defined by three characteristic parameters, an affinity (which we need not consider for purposes of this discussion), a maximal response (top) and a baseline (bottom). A simple hypothesis that provides an explanation for the YIL781 results in the KO mice is that the signaling dynamic range D (top minus bottom) is constrained near zero in absence of barrestin-2 and compensatory mechanisms by other modulatory systems regulate the observed DA-mediated locomotion (Figure 7c ). Therefore, not only is the attenuation of hyperlocomotion by ghrelin receptor barrestin-2-dependent, it apparently is also G protein independent and not rescued by redundancy of the remaining cellular barrestin-1.
In conclusion, the findings presented here identify separable behavioral changes in the addiction cycle that differ in their requirements for
barrestin-2 and demonstrate that the acute pharmacological ablation of its activity at the GHSR1a is not equivalent to its permanent genetic ablation. In addition, the notion that chronically targeting the GHSR1a with antagonists to alleviate adverse aspects on dopamine regulation occurring with drug addiction must be balanced by our data in KO mice suggesting that the modulatory ghrelin system may readjust to counter objectives in treatment. To be able to better achieve a long-term goal of using a drug that simultaneously reduce GHSR1a signaling and abnormal dopamine activity, we should first identify which of the G-protein or barrestin pathways provides the superior target and then tailor the pharmacological treatment to the more relevant pathway using functionally selective compounds that also maintain chronic barrestin activity. 
A U TH OR ' S ROLES
